David D. Deininger

Novel Inhibitors of Cholesterol Degradation in Mycobacterium tuberculosis Reveal How the Bacterium’s Metabolism Is Constrained by the Intracellular Environment

Brian C. VanderVen, Ruth J. Fahey, Wonsik Lee et al. · PLoS Pathogens · 2015 · 267 citations · Full text

Bacteriology, Molecular Biology, Metabolic Remodeling +17

Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity Relationships

Paul S. Charifson, Anne‐Laure Grillot, Trudy H. Grossman et al. · Journal of Medicinal Chemistry · 2008 · 222 citations · Full text

Bioorganic Chemistry, Antibacterial Activity, Molecular Biology +23

Inhibitors of hepatitis C virus NS3·4A protease 2. Warhead SAR and optimization

Robert B. Perni, J. PITLIK, Shawn Britt et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 62 citations · Full text

Immunology, Antiviral Drug Development, Hepatitis +9

Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506

David M. Armistead, Michael C. Badia, David D. Deininger et al. · Acta Crystallographica Section D Biological Crystallography · 1995 · 54 citations

Inhibitors of hepatitis C virus NS3·4A protease. Part 3: P2 proline variants

Robert B. Perni, Luc J. Farmer, Kevin M. Cottrell et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 52 citations · Full text

Viral Hepatitis, Antiviral Drug Development, Antiviral Therapy +9